Path Grand Rounds: A contemporary view of lumpectomy margin evaluation
This event has ended.
Stuart J. Schnitt, MD
Professor of Pathology, Harvard Medical School
Director, Division of Anatomic Pathology, Beth Israel Deaconess Medical Center
A contemporary view of lumpectomy margin evaluation
For more than 20 years, breast conserving therapy, consisting of lumpectomy and whole breast irradiation, has been a standard form of treatment for patients with early-stage invasive breast cancer. However, until very recently there was no general agreement as to what constitutes an adequate negative lumpectomy margin in such patients. In 2014, The Society of Surgical Oncology (SSO) and American Society of Radiation Oncology (ASTRO) published consensus guidelines to address this issue. It is important for pathologists and clinicians involved in the care of patients with breast cancer to understand these guidelines since they have the potential to decrease re-excision rates, improve cosmetic outcomes, and reduce healthcare costs.
Reference PMID: 24515565
After viewing this lecture, attendees should be able to:
1. Describe the technical and interpretive limitations in evaluation of breast lumpectomy margins.
2. Describe the current consensus guidelines for margins for patients with invasive breast cancer treated with breast conserving therapy.
3. Describe the current consensus guidelines for margins for patients with ductal carcinoma in situ treated with breast conserving therapy.